These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 31645346

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Association of PDGFRB Mutations With Pediatric Myofibroma and Myofibromatosis.
    Dachy G, de Krijger RR, Fraitag S, Théate I, Brichard B, Hoffman SB, Libbrecht L, Arts FA, Brouillard P, Vikkula M, Limaye N, Demoulin JB.
    JAMA Dermatol; 2019 Aug 01; 155(8):946-950. PubMed ID: 31017643
    [Abstract] [Full Text] [Related]

  • 24. Segmental overgrowth and aneurysms due to mosaic PDGFRB p.(Tyr562Cys).
    Chenbhanich J, Hu Y, Hetts S, Cooke D, Dowd C, Devine P, UCLA Clinical Genomics Center, Russell B, Kang SHL, Chang VY, Abla AA, Cornett P, Yeh I, Lee H, Martinez-Agosto JA, Frieden IJ, Shieh JT.
    Am J Med Genet A; 2021 May 01; 185(5):1430-1436. PubMed ID: 33683022
    [Abstract] [Full Text] [Related]

  • 25. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2006 Mar 01; 24(7):1195-203. PubMed ID: 16505440
    [Abstract] [Full Text] [Related]

  • 26. Late Relapse in Genetically Determined Infantile Myofibromatosis. A Case Report and Brief Focus on Recurrences.
    Conte A, De Padova D, Giglio S, Livellara V, Manzitti C, De Marco P, Capra V, Sorrentino S.
    J Pediatr Hematol Oncol; 2024 Oct 01; 46(7):e528-e530. PubMed ID: 39141797
    [Abstract] [Full Text] [Related]

  • 27. Prenatal genetic diagnosis of disseminated infantile myofibromatosis: a case report and literature review.
    Lü Y, Jiang Y, Wu H, Qi Q, Zhou X, Guo Q, Hao N, Liu J, Meng H.
    BMC Med Genomics; 2023 Aug 11; 16(1):185. PubMed ID: 37568122
    [Abstract] [Full Text] [Related]

  • 28. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
    Gosenca D, Kellert B, Metzgeroth G, Haferlach C, Fabarius A, Schwaab J, Kneba M, Scheid C, Töpelt K, Erben P, Haferlach T, Cross NC, Hofmann WK, Seifarth W, Reiter A.
    Genes Chromosomes Cancer; 2014 May 11; 53(5):411-21. PubMed ID: 24772479
    [Abstract] [Full Text] [Related]

  • 29. Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report.
    Bidadi B, Watson A, Weigel B, Oliveira A, Kirkham J, Arndt C.
    Pediatr Blood Cancer; 2020 Jun 11; 67(6):e28288. PubMed ID: 32307894
    [Abstract] [Full Text] [Related]

  • 30. Myofibromatosis presenting as reticulated vascular changes and subcutaneous atrophy in a patient with somatic mosaicism of PDGFRB mutation.
    Zhong CS, Song H, Weiss A, Tan WH, Coury S, Huang JT.
    Br J Dermatol; 2018 Dec 11; 179(6):1408-1409. PubMed ID: 29999524
    [No Abstract] [Full Text] [Related]

  • 31. Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis.
    Barry KK, Schienda J, Morrow JJ, Al-Ibraheemi A, Balkin DM, Church AJ, Eng W, Janeway KA, Kamihara J, Liang MG.
    Pediatr Blood Cancer; 2023 Jun 11; 70(6):e30262. PubMed ID: 36861440
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Mutations in PDGFRB and NOTCH3 are the first genetic causes identified for autosomal dominant infantile myofibromatosis.
    Lee JW.
    Clin Genet; 2013 Oct 11; 84(4):340-1. PubMed ID: 23865785
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. STAT1 modulates tissue wasting or overgrowth downstream from PDGFRβ.
    He C, Medley SC, Kim J, Sun C, Kwon HR, Sakashita H, Pincu Y, Yao L, Eppard D, Dai B, Berry WL, Griffin TM, Olson LE.
    Genes Dev; 2017 Aug 15; 31(16):1666-1678. PubMed ID: 28924035
    [Abstract] [Full Text] [Related]

  • 37. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
    Zou YS, Hoppman NL, Singh ZN, Sawhney S, Kotiah SD, Baer MR.
    Cancer Genet; 2017 Apr 15; 212-213():38-44. PubMed ID: 28449810
    [Abstract] [Full Text] [Related]

  • 38. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
    Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N.
    Exp Hematol; 2016 Mar 15; 44(3):177-88.e5. PubMed ID: 26703895
    [Abstract] [Full Text] [Related]

  • 39. Recurrent Somatic PDGFRB Mutations in Sporadic Infantile/Solitary Adult Myofibromas But Not in Angioleiomyomas and Myopericytomas.
    Agaimy A, Bieg M, Michal M, Geddert H, Märkl B, Seitz J, Moskalev EA, Schlesner M, Metzler M, Hartmann A, Wiemann S, Michal M, Mentzel T, Haller F.
    Am J Surg Pathol; 2017 Feb 15; 41(2):195-203. PubMed ID: 27776010
    [Abstract] [Full Text] [Related]

  • 40. Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.
    Yamazaki M, Nakaseko C, Takeuchi M, Ozawa S, Ishizuka Y, Hatanaka Y, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Ohwada C, Takeda Y, Mimura N, Iseki T, Fukazawa M, Sakaida E.
    Intern Med; 2019 Dec 01; 58(23):3449-3453. PubMed ID: 31327842
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.